Tecartus® CAR T-Cell Therapy Demonstrates OS Benefit In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial In R/R B-Cell Acute Lymphoblastic Leukemia February 22, 2023
2023 EBMT-EHA: Encouraging initial safety and efficacy data for point-of-care manufactured GLPG5201 CAR-T in rrCLL presented February 22, 2023
Successful Dosing of Final Patient in ACHIEVE Safety Cohort of TCB008 Trial Announced February 8, 2023
TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of CRR in R/R CLL Patients February 1, 2023
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology January 17, 2023
Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology January 4, 2023
Calquence approved in Japan for adults with treatment-naïve chronic lymphocytic leukaemia January 4, 2023
80% ORR reported in Final Cohort of Ph 1 Single Agent Trial of Annamycin for the Treatment of AML December 19, 2022
Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned December 13, 2022
U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Patients with R/R KMT2A- Rearranged (MLLr) Acute Leukemia December 12, 2022
FDA Approves REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with R/R AML with a Susceptible IDH1 Mutation December 5, 2022
Ph 3 trial of SYK inhibitor, entospletinib, for the treatment of newly diagnosed patients with NPM1-mutated AML to be discontinued November 16, 2022
Positive 1-Year and 2-Year OS Data for Patients with R/R AML in Ph 1 Actimab-A CLAG-M Combo Trial Announced November 16, 2022
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML November 2, 2022
Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies October 26, 2022
